NEW YORK (GenomeWeb News) – Exact Sciences today reported its revenues were flat for the second quarter year over year, while its net loss climbed sharply.

For the period ended June 30, the molecular diagnostics firm brought in revenues of $1 million, the same amount as it made during the quarter last year, matching Wall Street estimates.

All of the Madison, Wis.-based firm's revenues for the quarter were derived from license fees. It had no product royalty fees in the quarter compared to $6,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.